RemeGen Co., Ltd. (HKG:9995)

Market Cap	26.73B
Revenue (ttm)	2.05B
Net Income (ttm)	-1.47B
Shares Out	536.84M
EPS (ttm)	-2.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,638,500
Average Volume	10,511,841
Open	41.50
Previous Close	41.20
Day's Range	40.00 - 42.45
52-Week Range	10.20 - 46.90
Beta	0.59
RSI	61.16
Earnings Date	Apr 28, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 2,999
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY